Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 11/26 11:30:00 am
7785 GBX   -0.19%
05:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
03:31pASTRAZENECA : says working with regulators on best approach to lower dose regimen
RE
03:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : wins two approval recommendations from EU agency

10/19/2020 | 02:38am EST
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

Oct 19 (Reuters) - The European medicines watchdog has recommended approving AstraZeneca Plc's treatments for a form of heart failure and a lung disorder, the British drugmaker said on Monday.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approving Forxiga for treating a form of heart failure and Trixeo Aerosphere for a form of lung disorder known as "smoker's lung".

AstraZeneca's diabetes treatment Farxiga, known as Forxiga outside North America, is being recommended for an expanded approval as a treatment for a form of heart failure in adult patients with and without type-2 diabetes.

Trixeo Aerosphere, which is a triple-combination therapy, is already approved in Japan, China and the United States for patients with chronic obstructive pulmonary disease (COPD).

Known as "smoker's lung", COPD is a progressively worsening and potentially deadly condition that affects more than 380 million people worldwide and is primarily caused by smoking, but also by occupational hazards such as air pollution or chemical fumes.

While final approvals are up to the European Commission, it generally follows the CHMP's recommendation and endorses them within a couple of months.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Aditya Soni)


© Reuters 2020
All news about ASTRAZENECA PLC
05:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
03:31pASTRAZENECA : says working with regulators on best approach to lower dose regime..
RE
03:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
02:11pRussia's Sputnik V developers call on AstraZeneca to try combining vaccines
RE
01:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
12:51pASTRAZENECA : Top UK scientific adviser says AstraZeneca vaccine works
RE
11:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
10:58aANALYSIS : Questions over AstraZeneca's COVID-19 vaccine data risk delaying appr..
RE
10:06aWhy the Oxford Astrazeneca Vaccine Is Now a Global Gamechanger
AQ
09:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 46,6x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,48 $
Last Close Price 103,46 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC1.85%137 013
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-4.41%282 585
PFIZER INC.-1.59%203 048
NOVARTIS AG-11.88%202 620
MERCK & CO., INC.-11.97%202 555